Identification of Protein markers in ovarian cancer

Identification Of Protein Markers Suitable for the early detection of ovarian cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000519358

Enrollment

100

Registered

2008-10-03

Start date

2008-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to identify protein markers that are suitable for allowing early detection of ovarian cancer. Who is it for? You can join this study if you have either: (1) known ovarian cancer diagnosed from a previous pathology specimen. (2) an ovarian mass which may be benign or malignant. and you will be having surgical removal of either your ovary or ovaries (oophorectomy or ovariectomy) or your uterus (hysterectomy). Trial details: Participants will be requested to donate biological samples: blood, tissue, ascites (peritoneal cavity fluid), urine and uterine lavage (washings). This does not interfere with other diagnostic tests, or with the required medical or surgical treatment. Surgery will be performed in exactly same way, as if the samples had not been collected. Detection of ovarian cancer at its earliest stages provides a good prognosis for full recovery; however survival diminishes greatly when the cancer spreads beyond the ovary. Current ovarian cancer markers lack the accuracy needed to provide a suitable early detection test. This study uses new procedures to identify a number of candidate blood protein markers produced by ovarian cancers which may be suitable as early cancer markers.

Interventions

All patients undergoing this study will be having an oophorectomy or hysterectomy for a gynecological malignancy or benign condition. The participants will be requested to donate biological samples: blood , tissue, ascites,urine and uterine lavage which does not interfere with other diagnostic tests, nor does it interfere with medical or surgical treatment required. Surgery will be performed in exactly same way, as if the biological samples had not been collected.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Diagnosis

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

Patients who have known Ovarian cancer diagnosed from a previous pathology specimen OR Patients with an Ovarian mass which may be beningn or malignat.

Exclusion criteria

Inability to give consent

Outcome results